Antithrombotic treatments in patients with SARS-CoV-2 infection : from current evidence to reasonable recommendations - A position paper from the Italian Working Group on Atherosclerosis, Thrombosis and Vascular Biology
Given the high prevalence of preexisting cardiovascular diseases and the increased incidence of adverse cardiovascular events in patients hospitalized for SARS-CoV-2 infection, the identification of optimal antithrombotic approaches in terms of risk/benefit ratio and outcome improvement appears crucial in this setting. In the present position paper we collected current evidence from the literature to provide practical recommendations on the management of antithrombotic therapies (antiplatelet and anticoagulant) in various clinical contexts prevalent during the SARS-CoV-2 outbreak: in-home management of oral anticoagulant therapy; interactions between drugs used in the SARS-CoV-2 infection and antithrombotic agents; in-hospital management of antithrombotic therapies; diagnosis, risk stratification and treatment of in-hospital thrombotic complications.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
Giornale italiano di cardiologia (2006) - 21(2020), 7 vom: 01. Juli, Seite 489-501 |
| Sprache: |
Italienisch |
|---|
| Weiterer Titel: |
Terapie antitrombotiche in pazienti con infezione da SARS-CoV-2: dalle attuali evidenze alle ragionevoli raccomandazioni – Position paper del Gruppo di Studio Aterosclerosi, Trombosi e Biologia Vascolare |
|---|
| Beteiligte Personen: |
Patti, Giuseppe [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 29.06.2020 Date Revised 18.12.2020 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1714/3386.33634 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM311342922 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM311342922 | ||
| 003 | DE-627 | ||
| 005 | 20231225142040.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||ita c | ||
| 024 | 7 | |a 10.1714/3386.33634 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1037.xml |
| 035 | |a (DE-627)NLM311342922 | ||
| 035 | |a (NLM)32555564 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a ita | ||
| 100 | 1 | |a Patti, Giuseppe |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Antithrombotic treatments in patients with SARS-CoV-2 infection |b from current evidence to reasonable recommendations - A position paper from the Italian Working Group on Atherosclerosis, Thrombosis and Vascular Biology |
| 246 | 3 | 3 | |a Terapie antitrombotiche in pazienti con infezione da SARS-CoV-2: dalle attuali evidenze alle ragionevoli raccomandazioni – Position paper del Gruppo di Studio Aterosclerosi, Trombosi e Biologia Vascolare |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.06.2020 | ||
| 500 | |a Date Revised 18.12.2020 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Given the high prevalence of preexisting cardiovascular diseases and the increased incidence of adverse cardiovascular events in patients hospitalized for SARS-CoV-2 infection, the identification of optimal antithrombotic approaches in terms of risk/benefit ratio and outcome improvement appears crucial in this setting. In the present position paper we collected current evidence from the literature to provide practical recommendations on the management of antithrombotic therapies (antiplatelet and anticoagulant) in various clinical contexts prevalent during the SARS-CoV-2 outbreak: in-home management of oral anticoagulant therapy; interactions between drugs used in the SARS-CoV-2 infection and antithrombotic agents; in-hospital management of antithrombotic therapies; diagnosis, risk stratification and treatment of in-hospital thrombotic complications | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Fibrinolytic Agents |2 NLM | |
| 700 | 1 | |a Lio, Veronica |e verfasserin |4 aut | |
| 700 | 1 | |a Cavallari, Ilaria |e verfasserin |4 aut | |
| 700 | 1 | |a Gragnano, Felice |e verfasserin |4 aut | |
| 700 | 1 | |a Riva, Letizia |e verfasserin |4 aut | |
| 700 | 1 | |a Calabrò, Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Di Pasquale, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Pengo, Vittorio |e verfasserin |4 aut | |
| 700 | 1 | |a Rubboli, Andrea |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Giornale italiano di cardiologia (2006) |d 2006 |g 21(2020), 7 vom: 01. Juli, Seite 489-501 |w (DE-627)NLM16119561X |x 1972-6481 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2020 |g number:7 |g day:01 |g month:07 |g pages:489-501 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1714/3386.33634 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2020 |e 7 |b 01 |c 07 |h 489-501 | ||